1. Schloffer H (1907) Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr 20:621–624
2. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. doi: 10.1210/er.2005-9998
3. Biller BM, Molitch ME, Vance ML et al (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81(6):2338–2343. doi: 10.1210/jc.81.6.2338
4. Colao A, Di Sarno A, Landi ML et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579. doi: 10.1210/jc.82.11.3574
5. Colao A, Di Sarno A, Landi ML et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247–2252. doi: 10.1210/jc.85.6.2247